{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:12:45Z","timestamp":1789841565902,"version":"4.0.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T00:00:00Z","timestamp":1591401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T00:00:00Z","timestamp":1591401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s12029-020-00423-x","type":"journal-article","created":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T05:02:46Z","timestamp":1591419766000},"page":"316-319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Resected High-Risk Rectal GIST Harboring NTRK1 Fusion: a Case Report and Review of the Literature"],"prefix":"10.1007","volume":"52","author":[{"given":"Renata","family":"D\u2019Alpino Peixoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Amaral","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Henrique","family":"Cronemberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,6]]},"reference":[{"key":"423_CR1","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S0140-6736(13)60106-3","volume":"382","author":"H Joensuu","year":"2013","unstructured":"Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382:973\u201383. https:\/\/doi.org\/10.1016\/S0140-6736(13)60106-3.","journal-title":"Lancet"},{"key":"423_CR2","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrc3143","volume":"11","author":"CL Corless","year":"2011","unstructured":"Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11:865\u201378. https:\/\/doi.org\/10.1038\/nrc3143.","journal-title":"Nat Rev Cancer"},{"key":"423_CR3","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/S0140-6736(07)60780-6","volume":"369","author":"BP Rubin","year":"2007","unstructured":"Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2007;369:1731\u201341. https:\/\/doi.org\/10.1016\/S0140-6736(07)60780-6.","journal-title":"Lancet"},{"key":"423_CR4","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1200\/JCO.2006.06.2265","volume":"24","author":"MC Heinrich","year":"2006","unstructured":"Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006;24:4764\u201374.","journal-title":"J Clin Oncol"},{"key":"423_CR5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12967-016-1075-6","volume":"14","author":"E Shi","year":"2016","unstructured":"Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G, et al. FGFR1 and NTRK3 actionable alterations in \"wild-type\" gastrointestinal stromal tumors. J Transl Med. 2016;14:339.","journal-title":"J Transl Med"},{"key":"423_CR6","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1001\/jamaoncol.2016.0256","volume":"2","author":"SA Boikos","year":"2016","unstructured":"Boikos SA, Pappo AS, Killian JK, LaQuaglia MP, Weldon CB, George S, et al. Molecular subtypes of KIT\/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol. 2016;2:922\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2016.0256.","journal-title":"JAMA Oncol"},{"key":"423_CR7","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/path.4677","volume":"238","author":"M Brenca","year":"2016","unstructured":"Brenca M, Rossi S, Polano M, Gasparotto D, Zanatta L, Racanelli D, et al. Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST. J Pathol. 2016;238:543\u20139. https:\/\/doi.org\/10.1002\/path.4677.","journal-title":"J Pathol"},{"key":"423_CR8","doi-asserted-by":"publisher","unstructured":"Casali PG, Abecassis N, Bauer S et al (2018) Gastrointestinal stromal tumours: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29 Suppl 4:iv68-iv78. https:\/\/doi.org\/10.1093\/annonc\/mdy095.","DOI":"10.1093\/annonc\/mdy095"},{"key":"423_CR9","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Soft tissue sarcoma. Version 6.2019 \u2013 February 10, 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sarcoma.pdf Accessed Apr 8, 2020."},{"key":"423_CR10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","volume":"21","author":"DS Hong","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. 2020;21:531\u201340. https:\/\/doi.org\/10.1016\/S1470-2045(19)30856-3.","journal-title":"Lancet Oncol"},{"key":"423_CR11","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S1470-2045(16)00075-9","volume":"17","author":"O Mir","year":"2016","unstructured":"Mir O, Cropet C, Toulmonde M, Cesne AL, Molimard M, Bompas E, et al. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicenter, open-label phase 2 trial. Lancet Oncol. 2016;17:632\u201341. https:\/\/doi.org\/10.1016\/S1470-2045(16)00075-9.","journal-title":"Lancet Oncol"},{"key":"423_CR12","doi-asserted-by":"publisher","first-page":"310","DOI":"10.18632\/oncotarget.864","volume":"4","author":"GS Falchook","year":"2013","unstructured":"Falchook GS, Trent JC, Heinrich MC, et al. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget. 2013;4:310\u20135. https:\/\/doi.org\/10.18632\/oncotarget.864.","journal-title":"Oncotarget"},{"key":"423_CR13","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1172\/JCI60578","volume":"123","author":"WJ Jessen","year":"2013","unstructured":"Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest. 2013;123:340\u20137. https:\/\/doi.org\/10.1172\/JCI60578.","journal-title":"J Clin Invest"},{"key":"423_CR14","doi-asserted-by":"publisher","first-page":"8387","DOI":"10.1073\/pnas.0803383105","volume":"105","author":"C Tarn","year":"2008","unstructured":"Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A. 2008;105:8387\u201392. https:\/\/doi.org\/10.1073\/pnas.0803383105.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-020-00423-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-020-00423-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-020-00423-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T13:12:30Z","timestamp":1628601150000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-020-00423-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,6]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["423"],"URL":"https:\/\/doi.org\/10.1007\/s12029-020-00423-x","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,6]]},"assertion":[{"value":"6 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}